Premium
ORIGINAL ARTICLE: Pilot comparison of 18 F‐fluorocholine and 18 F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer
Author(s) -
Beauregard JM,
Williams SG,
DeGrado TR,
Roselt P,
Hicks RJ
Publication year - 2010
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/j.1754-9485.2010.02178.x
Subject(s) - medicine , prostate cancer , nuclear medicine , positron emission tomography , fluorodeoxyglucose , radiology , pet ct , prostate , cancer , positron emission tomography computed tomography
Conventional imaging (CI) is known to have limitations with respect to staging of patients with primary or relapsed prostate cancer. Positron emission tomography/computed tomography (PET/CT) with 18 F‐flurodeoxyglucose (FDG) is also often suboptimal because of low tracer avidity, but 18 F‐fluorocholine (FCH) appears to be a promising alternative molecular imaging probe. We report a prospective pilot study of PET/CT comparing both tracers for staging and restaging of patients with prostate cancer. Methods: Sixteen prostate cancer patients were evaluated (7 for staging and 9 for restaging). All patients also underwent CI, comprising at least an abdominopelvic CT and a bone scan. All imaging results and other relevant data were extracted from the imaging reports and medical charts. Results: Based on all imaging‐detected disease sites, both FCH‐PET/CT and FDG‐PET/CT (79%) were more sensitive than CI (14%), with the highest number of sites of nodal and distant disease on FCH PET/CT. FCH‐PET/CT alone would have provided sufficient clinical information to form an appropriate management plan in 88% of cases, as compared with 56% for CI. Conclusion: FCH‐PET/CT has the potential to impact on the management of patients with prostate cancer significantly more often than CI.